InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.06
(
-0.09%
)
Bitcoin
66,308.81
(
-0.50%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: None

Thursday, 05/05/2011 10:57:21 AM

Thursday, May 05, 2011 10:57:21 AM

Post# of 80490
One thing that I hope the analysts pick up on is that current second line therapies have a median response rate of only 1 to 2 years. I strongly suspect that ponatinibs median response rate is going to be much closer to the current first-line drugs e.g 5+ years. Consequently, I think the analysts are significantly underestimating ponatinibs commercial opportunity.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up